Abstract：Objective To investigate the effect of different initial dose of Paricalcitol in the treatment of secondary hyperparathyroidism (SHPT).Methods A total of 80 patients with hemodialysis and SHPT who admitted to Yichun People′s Hospital of Jiangxi Province from August 2018 to August 2019 were selected as the research objects and divided into the control group,small-dose group,moderate-dose group and large-dose group according to the random number table method,with 20 cases in each group.The control group was treated with placebo,small-dose group was treated with initial dose of 0.04 μg/kg Paricalcitol,moderate-dose group was treated with initial dose of 0.08 μg/kg paricalcitol,and large-dose group was treated with initial dose of 0.1 μg/kg Paricalcitol.After 3 months of treatment,the efficacy,qualified rate of intact parathyroid hormone (iPTH) and the adverse reactions were compared among the four groups.Results After treatment,the total effective rate of moderate-dose group was higher than those of the control group,small-dose group and large-dose group,and the differences were statistically significant (P<0.05).The qualified rate of iPTH in moderate-dose group was higher than those of the control group,small-dose group and large-dose group,and the differences were statistically significant (P<0.05).There were no statistically significant differences in the incidence of adverse reactions of the small-dose group,moderate-dose group and large-dose group (P>0.05).Conclusion The moderate initial dose of Paricalcitol (0.08 μg/kg) for patients with hemodialysis and SHPT has better curative effect and higher qualified rate of iPTH,and not increase the risk of adverse reactions.
魏培丹；贾辰；陈效；徐石张；易建伟；罗子云；何志红. 帕立骨化醇不同起始剂量治疗继发性甲状旁腺功能亢进的效果[J]. 中国当代医药, 2021, 28(4): 70-72.
WEI Pei-dan；JIA Chen；CHEN Xiao XU；Shi-zhang ；YI Jian-wei ；LUO Zi-yun； HE Zhi-hong. Effect of different initial dose of Paricalcitol in the treatment of secondary hyperparathyroidism. 中国当代医药, 2021, 28(4): 70-72.
京公网安备 11010502046607号